Caixin
Oct 07, 2022 02:45 AM
BUSINESS

China's Biggest Hepatitis B Vaccine Maker Gains 2.1% in Sharp Swing on Hong Kong Debut

A doctor injects hepatitis B vaccine in Xingtai, Hebei province, on Oct. 1, 2022.
A doctor injects hepatitis B vaccine in Xingtai, Hebei province, on Oct. 1, 2022.

Shares of AIM Vaccine Co. Ltd., China’s second-largest vaccine maker, jumped 2.1% on its Hong Kong debut Thursday after a bumpy initial public offering.

The company raised a net HK$70.01 million ($9.84 million) of from selling 9.7 million shares at HK$16.16 per share. The stock opened at HK$15 per share and recovered over the day.

The vaccine maker joined a growing list of biopharmaceutical companies that have opted to go public with low issuance volumes in the face of a cooling IPO market and limited external financing.

You've accessed an article available only to subscribers
VIEW OPTIONS
Share this article
Open WeChat and scan the QR code
NEWSLETTERS
Get our CX Daily, weekly Must-Read and China Green Bulletin newsletters delivered free to your inbox, bringing you China's top headlines.

We ‘ve added you to our subscriber list.

Manage subscription
PODCAST
China Stories: The Rural Hardship Behind the Mine Murders That Shocked China
00:00
00:00/00:00